(OCS) Oculis Holding Ordinary - Ratings and Ratios

Oculis Holding AG, a clinical-stage biopharmaceutical company, is advancing a pipeline of innovative drug candidates targeting ophthalmic diseases. Its lead product, OCS-01, is a topical dexamethasone optireach formulation currently in Phase 3 clinical trials for diabetic macular edema, a condition causing vision loss in diabetic patients. The company is also developing OCS-02, a topical biologic candidate in Phase 2b trials for dry eye disease, a common and often debilitating condition. Additionally, Oculis is exploring OCS-05, a disease-modifying neuroprotective agent with potential applications in glaucoma, dry age-related macular degeneration, diabetic retinopathy, and acute optic neuritis.

Based in Zug, Switzerland, Oculis Holding AG is listed on the NASDAQ under the ticker symbol OCS. The company operates in the biotechnology sector, focusing on ophthalmology, a specialized yet high-value market. Its pipeline addresses both front-of-the-eye (e.g., dry eye) and back-of-the-eye (e.g., diabetic macular edema) conditions, positioning it as a diversified player in the ophthalmic drug development space.

From a financial perspective, Oculis Holding AG has a market capitalization of $928.80 million as of the latest data. The company currently reports a price-to-book (P/B) ratio of 8.91 and a price-to-sales (P/S) ratio of 1070.05, reflecting its pre-revenue stage as a clinical-stage biotech firm. The lack of trailing and forward P/E ratios indicates that the company is not yet generating profits, which is typical for early-stage biotechnology companies focused on drug development.